SCHEMBL1490650

SCHEMBL1490650

COC(=O)c1c(NC(=O)c2ccc(Cl)cc2)csc1-c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.52
LMNA P02545 3/20 0.52
KMT2A Q03164 3/20 0.52
POLB P06746 1/20 0.52
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
TSHR P16473 1/20 0.48
CYP2C19 P33261 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 1/20 0.47
CNR2 P34972 2/20 0.47
PTGS1 P23219 1/20 0.46
KCNMA1 Q12791 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
ATM Q13315 1/20 0.46
KDM4E B2RXH2 3/20 0.46
ADCY1 Q08828 1/20 0.44
TP53 P04637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1490441 0.89 LMNA (0.52) MAPTLMNAKMT2APOLBCYP1A2
SCHEMBL1490520 0.87 MEN1 (0.49) MAPTLMNAKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1490393 0.87 MEN1 (0.49) MAPTLMNAKMT2ASMN1; SMN2ALDH1A1
SCHEMBL1490469 0.83 MAPT (0.74) MAPTLMNAKMT2APOLBCYP1A2
SCHEMBL1490509 0.80 KMT2A (0.55) MAPTLMNAKMT2ASMN1; SMN2ALDH1A1
SCHEMBL3631128 0.80 MAPT (0.66) MAPTLMNAKMT2ATSHRALDH1A1
SCHEMBL12756878 0.80 KMT2A (0.56) MAPTLMNAKMT2ACYP1A2CYP2C19
SCHEMBL15477195 0.78 KDM4E (0.47) MAPTLMNAKMT2APOLBCYP1A2
SCHEMBL1490436 0.78 MAPT (0.52) MAPTLMNAKMT2APOLBCYP1A2
SCHEMBL1490525 0.78 MEN1 (0.64) MAPTLMNAKMT2APOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 US disclosed
US-8618307-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2013-12-31 US disclosed
EP-2477982-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM Calcimedica, Inc. (US) 2012-07-25 EP disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 WO disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 MAPT 1478/4885LMNA 1306/4885KMT2A 4706/4885
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 MAPT 1478/4885LMNA 1306/4885KMT2A 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.